Skip to content
Screener

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$21K-98.4%
Altimmune logo
AltimmuneALT
$78.47M+130%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$12.08M+3,360%
Wave Life Sciences logo
Wave Life SciencesWVE
$330K-97.2%
Arrowhead Research logo
Arrowhead ResearchARWR
$795.72M+761%

Other financials

Income statement

See full
Revenue$364.3M+71.2%
Gross profit$43.5M
Operating income-$56.3M-19.3%
Net income-$57.9M-37.0%
EPS (diluted)-$1.99-4.7%

Balance sheet

See full
Cash & equivalents$292.9M+53.2%
Total debt$377.9M+179%
Total equity$523.7M-24.7%
Total assets$1.2B+22.6%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$4.3M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.88B+57.6%
Enterprise value$11.96B+59.9%
P/S9.3×-5.4×

Profitability

See full
Gross margin96.5%
Operating margin-25.1%-9.2pp
Net margin-25.3%-8.8pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-53.3%+47.0pp
Debt / equity0.7×+0.5×
Current ratio3.2×-1.9×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 9:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050845
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Net cash provided by investing activities226,386211,736
Cash flows from financing activities:
Proceeds from exercise of common stock options5,44110,381
Net cash provided by financing activities5,44110,381
Effect of exchange rate changes on cash, cash equivalents and restricted cash1,377
Net increase in cash, cash equivalents, and restricted cash89,09886,174
Cash, cash equivalents, and restricted cash at beginning of period203,783105,019
Cash, cash equivalents, and restricted cash at end of period$292,881$191,193

Item 1. Financial Statements (Unaudited):

FAQ

What is Madrigal Pharmaceuticals, Inc.'s financing cash flow?
Madrigal Pharmaceuticals, Inc. (MDGL) reported financing cash flow of $3.11M in Q2 2026.
How has Madrigal Pharmaceuticals, Inc.'s financing cash flow changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s financing cash flow increased by 78.7% year-over-year, from $1.74M to $3.11M.
What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s financing cash flow?
Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s financing cash flow has grown at a 10.6% compound annual growth rate (CAGR), from $171.24M to $255.98M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Madrigal Pharmaceuticals, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude